Immune Tolerance Network

$5,707,872UM1FY2025AINIH

Benaroya Research Inst At Virginia Mason, Seattle WA

Investigators

Jane Hoyt Bucknercontact Mark S Anderson

Linked publications, trials & patents

Paper 39668949 Paper 39167668 Paper 38937521 Paper 38871688 Paper 38767983 Paper 38704098 Paper 38693758 Paper 38460680 Paper 38182056 Paper 38181729 Paper 37946302 Paper 37886513 Paper 37805522 Paper 37782353 Paper 37751304 Paper 37739311 Paper 37589918 Paper 37460024 Paper 37365013 Paper 37355988 Paper 37336058 Paper 37295474 Paper 37146884 Paper 37003475 Paper 36920087 Paper 36740326 Paper 36732171 Paper 36608983 Paper 36521802 Paper 36521801 Paper 36502801 Paper 36466872 Paper 36442768 Paper 36435990 Paper 36403663 Paper 36384652 Paper 36321870 Paper 36281741 Paper 36263023 Paper 36228295 Paper 36223848 Paper 36119087 Paper 36108922 Paper 36100133 Paper 36041516 Paper 35977774 Paper 35944894 Paper 35934070 Paper 35819312 Paper 35765165 Paper 35690369 Paper 35659939 Paper 35605816 Paper 35390476 Paper 35173258 Paper 35131513 Paper 35119937 Paper 35065784 Paper 35058150 Paper 35000772 Paper 34981778 Paper 34974934 Paper 34806648 Paper 34804070 Paper 34788079 Paper 34747368 Paper 34675423 Paper 34618687 Paper 34616405 Paper 34528383 Paper 34326847 Paper 34324441 Paper 34214479 Paper 33991353 Paper 33982909 Paper 33819508 Paper 33658358 Paper 33592205 Paper 33556344 Paper 33504809 Paper 33471075 Paper 33436162 Paper 33351781 Paper 33301420 Paper 33280227 Paper 32969204 Paper 32873972 Paper 32841219 Paper 32828589 Paper 32786149 Paper 32777389 Paper 32755035 Trial NCT05027815 Trial NCT04827979 Trial NCT04391309 Trial NCT04047628 Trial NCT03654040 Trial NCT03504241 Trial NCT03222492 Trial NCT02743793

Abstract

Jane Hoyt Buckner, MD (Contact) Mark S. Anderson, MD NIDDK Supplemental Funding Request 5UM1AI109565-12 Project Summary / Abstract The mission of the Immune Tolerance Network (ITN) is to advance the clinical applicaÆon of immune tolerance by conducÆng high-quality clinical trials of emerging therapeuÆcs based on testable mechanisÆc hypotheses. The ITN is designed to invesÆgate a range of diseases across the immunologic spectrum through the integraÆon of innovaÆve clinical studies and cuÆ«ng- edge immunologic analyses. Since its incepÆon, one of the areas of interest of the ITN has been Type 1 Diabetes (T1D) with a focus to successfully enhance the development of tolerance therapies. We uÆlize a collaboraÆve structure involving hundreds of invesÆgators, advisors, and clinical sites and mechanisÆc laboratories working in tandem with a core group of ITN staï¬, operaÆng a program that is both scienÆï¬cally and ï¬nancially eï¬cient. Our intenÆon is to evolve our current strategies into the next generaÆon of planned trials, as well as operate a ï¬exible, future-focused organizaÆon, poised to lead and adopt innovaÆons. Our approachâevaluaÆng novel tolerance therapeuÆcs in clinical seÆ«ngs while simultaneously invesÆgaÆng the geneÆc and immunologic mechanisms of disease and their response to therapyâprovides a robust framework for generaÆng cross-disease and cross-disciplinary insights. This strategy is aimed at acceleraÆng the development of new therapeuÆc opÆons for major diseases. With lead insÆtuÆonal commitment from the Benaroya Research InsÆtute and the University of California San Francisco, and parÆcipaÆon of more than 20 other major insÆtuÆons represented in leadership and major advisory roles, the ITN strives to conÆnue to successfully pioneer high impact clinical trials and mechanisÆc studies in T1D.

View original record on NIH RePORTER →